Metra's bone disease test reimbursed in Japan
This article was originally published in Clinica
Executive Summary
Metra Biosystems' Osteolinks-BAP test has been approved for reimbursement in Japan. It is the first enzyme immunoassay marketed in the country to use blood levels of bone alkaline phosphatase as a marker for bone formation.